Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Ventyx is focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. Its lead candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor that it believes has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. The company plans to develop VTX958 initially for psoriasis, psoriatic arthritis, and Crohn's disease. Ventyx has completed the single-ascending dose portion of its Phase 1 trial for VTX958 and expects to initiate the multiple-ascending dose part of this trial in the 4Q21.
The Encinitas, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol VTYX. Ventyx Biosciences filed confidentially on August 20, 2021. Jefferies, Evercore ISI, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.